<?xml version='1.0' encoding='utf-8'?>
<document id="23584886"><sentence text="Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole."><entity charOffset="156-168" id="DDI-PubMed.23584886.s1.e0" text="ketoconazole" /></sentence><sentence text="Ketoconazole is a potent CYP3A inhibitor used to assess the contribution of CYP3A to drug clearance and quantify the increase in drug exposure due to a strong inhibitor"><entity charOffset="0-12" id="DDI-PubMed.23584886.s2.e0" text="Ketoconazole" /></sentence><sentence text=" Physiologically based pharmacokinetic (PBPK) models have been used to evaluate treatment regimens resulting in maximal CYP3A inhibition by ketoconazole but have reached different conclusions"><entity charOffset="140-152" id="DDI-PubMed.23584886.s3.e0" text="ketoconazole" /></sentence><sentence text=" We compare two PBPK models of the ketoconazole-midazolam interaction, model 1 (Chien et al"><entity charOffset="35-47" id="DDI-PubMed.23584886.s4.e0" text="ketoconazole" /></sentence><sentence text=", 2006) and model 2 implemented in Simcyp (version 11), to predict 16 published treatment regimens" /><sentence text=" With use of model 2, 41% of the study point estimates of area under the curve (AUC) ratio and 71% of the 90% confidence intervals were predicted within 1" /><sentence text="5-fold of the observed, but these increased to 82 and 100%, respectively, with model 1" /><sentence text=" For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0"><entity charOffset="5-14" id="DDI-PubMed.23584886.s8.e0" text="midazolam" /><entity charOffset="44-53" id="DDI-PubMed.23584886.s8.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.23584886.s8.e0" e2="DDI-PubMed.23584886.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23584886.s8.e0" e2="DDI-PubMed.23584886.s8.e1" /></sentence><sentence text="97, whereas model 1 predicted 17 and 0" /><sentence text="90, respectively, which are more consistent with observed data" /><sentence text=" On the basis of model 1, ketoconazole (400 mg QD) for at least 3 days and substrate administration within 2 hours is required for maximal CYP3A inhibition"><entity charOffset="26-38" id="DDI-PubMed.23584886.s11.e0" text="ketoconazole" /></sentence><sentence text=" Ketoconazole treatment regimens that use 200 mg BID underestimate the systemic fraction metabolized by CYP3A (0"><entity charOffset="1-13" id="DDI-PubMed.23584886.s12.e0" text="Ketoconazole" /></sentence><sentence text="86 versus 0" /><sentence text="90) for midazolam" /><sentence text=" The systematic underprediction also applies to CYP3A substrates with high bioavailability and long half-lives" /><sentence text=" The superior predictive performance of model 1 reflects the need for accumulation of ketoconazole at enzyme site and protracted inhibition"><entity charOffset="86-98" id="DDI-PubMed.23584886.s16.e0" text="ketoconazole" /></sentence><sentence text=" Model 2 is not recommended for inferring optimal study design and estimation of fraction metabolized by CYP3A" /><sentence text="" /></document>